Reby Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Reby Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$69K	Buy	+456	New	+$65.2K	0.02%	188

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

Reby Advisors's IBB Position: Q4 2020 in Review

Reby Advisors opened a new position in iShares Biotechnology ETF (IBB) in Q4 2020: 456 shares worth $69K. The stake represents 0.02% of the portfolio and ranks #188 among its holdings.

856 funds tracked by Wall St. Rank hold IBB as of Q4 2020.

Reby Advisors held 456 shares of iShares Biotechnology ETF worth $69K as of Q4 2020.
iShares Biotechnology ETF was a new Reby Advisors position in Q4 2020.
iShares Biotechnology ETF made up 0.02% of Reby Advisors's portfolio in Q4 2020, its #188 holding.
856 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2020.

Based on Reby Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.